Immunity War: A Novel Therapy for Lymphoma Using T-cell Bispecific Antibodies.
The activity of T-cell-mediated immunotherapies in B-cell lymphoma has been limited to date. The novel bispecific antibody CD20-TCB has a 2:1 antibody design to maximize T-cell engagement and demonstrates activity in preclinical models. This may represent a novel therapeutic approach for patients with relapsed/refractory non-Hodgkin lymphoma (NHL). Clin Cancer Res; 24(19); 4631-2. ©2018 AACR See related article by Bacac et al., p. 4785.